4,554 Shares in Catalent, Inc. (NYSE:CTLT) Acquired by B. Metzler seel. Sohn & Co. Holding AG

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Catalent, Inc. (NYSE:CTLT) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,554 shares of the company’s stock, valued at approximately $276,000.

A number of other hedge funds also recently modified their holdings of the business. Quest Partners LLC raised its position in Catalent by 289.8% during the third quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock valued at $2,986,000 after buying an additional 36,652 shares during the period. Natixis Advisors LLC purchased a new stake in shares of Catalent in the third quarter worth approximately $1,287,000. Mizuho Markets Americas LLC acquired a new stake in shares of Catalent during the third quarter worth approximately $30,285,000. CIBC Asset Management Inc grew its position in Catalent by 7.9% during the third quarter. CIBC Asset Management Inc now owns 25,173 shares of the company’s stock valued at $1,525,000 after purchasing an additional 1,846 shares in the last quarter. Finally, ING Groep NV increased its stake in Catalent by 162.5% in the 3rd quarter. ING Groep NV now owns 1,130,504 shares of the company’s stock valued at $68,475,000 after buying an additional 699,851 shares during the period.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CTLT. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird reissued a “neutral” rating and set a $63.50 price objective on shares of Catalent in a research report on Tuesday, September 24th. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, StockNews.com lowered Catalent from a “hold” rating to a “sell” rating in a report on Friday. One research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $63.40.

Insider Activity

In related news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. This represents a 5.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is owned by insiders.

Catalent Price Performance

Shares of NYSE:CTLT opened at $61.24 on Tuesday. The stock has a market capitalization of $11.12 billion, a P/E ratio of -27.10, a P/E/G ratio of 2.42 and a beta of 1.16. The business has a 50-day moving average of $59.81 and a two-hundred day moving average of $58.32. Catalent, Inc. has a fifty-two week low of $36.74 and a fifty-two week high of $61.50. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the business posted ($0.10) earnings per share. The firm’s revenue was up 4.2% on a year-over-year basis. On average, equities research analysts predict that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.